Skip to content

The moderating effect of meditation on depressive symptoms and Neuro-immune interaction in depressed college students

The moderating effect of meditation on depressive symptoms and Neuro-immune interaction in depressed college students

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005269
Enrollment
Unknown
Registered
2021-09-04
Start date
2021-09-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depressive state

Interventions

Sponsors

Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 30 Years

Inclusion criteria

Inclusion criteria: 1. Depressed college students (PHQ-9 scale score > 10 points and 7 points and < 24 points), the subjects were tested by clinical psychologists from the Psychiatry Department of Beijing Liangxiang Hospital. Scale assessment and enrollment screening; 2. Those who are not required to receive antidepressant treatment in a depressed state; 3. With/without anxiety; 4. Those between the ages of 18 and 30; 5. All research subjects have not used antidepressant drugs within 6 months before the start of the project, and have not taken any drugs related to the treatment of depression during the course of the project until the end of sampling, and have not used any drugs within 1 week before sampling ; 6. Subjects should meet the inclusion criteria for fMRI: right-handed; no claustrophobia; no metal in the body (fillings are allowed); 7. Those who participated voluntarily and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Those with organic mental disorder, schizophrenia and bipolar disorder, psychoactive substances and depressive disorders caused by non-addictive substances; 2. Depressed state caused by major life changes or major events; 3. Women who are pregnant or planning to become pregnant and lactating women; 4. Combined with serious primary diseases such as liver, kidney, hematopoietic system and endocrine system; 5. Patients with moderate to severe or severe depression or those who need antidepressant treatment; 6. Those who are seriously ill and require emergency treatment; 7. Those who are paranoid and judged by researchers to be unsuitable for meditation training; 8. Patients who participated in other clinical research projects within 3 months.

Design outcomes

Primary

MeasureTime frame
HAMD Depression Scale Score;

Secondary

MeasureTime frame
Plasma inflammatory factors TNF-a, IL-1ß, IL-6, IFN-?, IL-17 levels in plasma;Brain default mode network resting-state functional connectivity;HAMD Depression Scale Score;Plasma levels of serotonin, dopamine, glutamine and norepinephrine;PHQ-9 Depression Screening Scale Score;Plasma untargeted metabolome assay;Proportion of Th1 lymphocytes and Th17 lymphocytes in peripheral blood;Baker Anxiety Inventory (BAI) Score;

Countries

China

Contacts

Public ContactJia Wenrui

Beijing University of Chinese Medicine

jwr333@yeah.net+86 13161139233

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026